Test Price
2,800 AED✅ Home Collection Available
DNAI2 Gene Primary Ciliary Dyskinesia Type 9 Genetic Test in UAE | 2800 AED | DHA Licensed Lab
Executive Summary & Core Metrics
Executive Summary: This single‑gene NGS test detects pathogenic variants in DNAI2 causing primary ciliary dyskinesia type 9, performed under ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139) and DHA‑licensed facility (License 1143).
✓ Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited Processing
✓ Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Daily 8 AM – 11 PM)
✓ Clinical Guidance: Telephonic Post‑Test Clinical Guidance in result interpretation
✓ Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731
Test Overview & Methodology
The DNAI2 NGS test identifies mutations in the gene responsible for primary ciliary dyskinesia type 9, a disorder of motile cilia that leads to chronic otitis, sinusitis, and bronchiectasis. This genetic test is essential for accurate diagnosis and management of patients with recurrent respiratory infections.
| Feature | Our DNAI2 NGS Test | Closest Alternative |
|---|---|---|
| Methodology | Next Generation Sequencing (full gene, exon ±10 bp splice sites) | Sanger sequencing (limited to known hotspots) or whole‑exome sequencing (broader, slower) |
| Diagnostic Precision | 99.9% sensitivity; detects SNVs, indels, and copy‑number variants | Variable; may miss deep intronic or regulatory variants |
| Turnaround Time | 3–4 weeks (ISO‑accelerated reporting) | 6–8 weeks (standard commercial lab) |
| UAE Compliance | MOHAP/DHA licensed, ISO 9001:2015, Federal Decree-Law No. 45 of 2021 on PDPL, Federal Law No. 2 of 2019 on ICT in Health, Federal Decree-Law No. 4 of 2016 on Medical Liability | Often lacks local regulatory clarity |
Physician Insight & Safety Protocols
“As a Consultant Medical Genetics, I emphasize that a positive DNAI2 result must be correlated with clinical findings – electron microscopy of ciliary ultrastructure and high‑speed video microscopy remain essential for confirming primary ciliary dyskinesia. Never stop prescribed medications without consulting your clinician, because children with suspected PCD often require immediate respiratory support. The test reveals risk, not destiny, and we guide every patient through responsible post‑test counselling.” – Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Advisory: Do Not Discontinue Prescribed Medications
Do not discontinue prescribed medication (antibiotics, mucolytics, or bronchodilators) without consulting your doctor. Abrupt cessation can lead to acute respiratory deterioration.
Exclusion Criteria & Emergency Red Flags
- Individuals unable to provide valid informed consent or assent (mandatory genetic counselling required per Federal Decree-Law No. 4 of 2016 on Medical Liability).
- Acute severe respiratory distress, hypoxaemia, or status asthmaticus – stabilise first, then test.
- Unconfirmed family history without prior ENT/pulmonology workup.
- If the patient develops sudden hearing loss, high fever with productive cough, or cyanosis, seek emergency care immediately.
Patient FAQ & Clinical Guidance
1. What does this test actually look for and how is it done?
It sequences the entire DNAI2 gene using Next Generation Sequencing from a single blood drop on an FTA card or EDTA tube. The test covers all coding exons and adjacent splice sites, interpreted by clinical geneticists following DHA‑approved guidelines.
2. Who should consider taking this genetic test?
Adults and children with recurrent otitis media, chronic sinusitis, bronchiectasis, or situs inversus, especially when a sibling or parent is affected, benefit most from this targeted DNAI2 analysis. A pre‑test genetic counselling session is mandatory to draw a pedigree and confirm clinical suspicion.
3. How fast will I receive my results and what support is provided?
Results are ready in 3–4 weeks, delivered through a secure portal with a telephonic clinical guidance session to explain implications and next steps. Our DHA‑licensed team remains available via WhatsApp at +971545488731 for result interpretation and insurance billing queries.
UAE Regulatory & Data Privacy Adherence
This test is fully compliant with UAE federal data protection and health information laws. Patient data is handled in accordance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All clinical procedures adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability, ensuring patient safety and informed consent. DNA Labs UAE operates under DHA Facility License No. 1143 and ISO 9001:2015 quality management system.
Clinical & Logistical Metadata
| Test Name | DNAI2 Gene Primary Ciliary Dyskinesia Type 9 Genetic Test |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Whole Blood (FTA Card or EDTA tube) |
| Methodology Used | Next Generation Sequencing (full gene, exon ±10 bp splice sites) |
| ICD-10-CM Code | J98.09 (Primary ciliary dyskinesia) |
| LOINC Code | 21656-2 (DNAI2 gene mutation analysis) |
| DHA Facility License & Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians